Motivated by the potential therapeutic use of CD38-targeting antibodies for the treatment of SLE, this study dissected the expression profiles of CD38 in peripheral blood immune cells and described dysregulated CD38 expression in SLE patients compared to healthy controls. The gene discussed is CD38; the disease is systemic lupus erythematosus.